A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)
Phase 3
Completed
- Conditions
- Osteoarthritis
- Registration Number
- NCT00092352
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of osteoarthritis of the knee.
- Detailed Description
The duration of treatment is 6 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 395
Inclusion Criteria
- Osteoarthritis of the knee which requires treatment with medication for pain relief
Exclusion Criteria
- Any known allergy to the study drug
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Osteoarthritis (OA) of the knee as measured by Patient Global Assessment of Response to Therapy (PGART) and WOMAC VA 3.0 over 6 weeks of treatment.
- Secondary Outcome Measures
Name Time Method WOMAC Question #1 over 6 wks of treatment. OA of the knee as measured by PGART over 6 wks of treatment.